| 1 OS‐overall analysis |
12 |
5976 |
Hazard Ratio (Fixed, 95% CI) |
0.90 [0.84, 0.96] |
| 2 OS‐sensitivity analysis by random‐effects model |
12 |
5976 |
Hazard Ratio (Random, 95% CI) |
0.89 [0.81, 0.97] |
| 3 OS‐sensitivity analysis by excluding studies with high risk of bias |
11 |
5758 |
Hazard Ratio (Fixed, 95% CI) |
0.90 [0.85, 0.96] |
| 4 OS‐subgroup analysis by dose of IDA |
12 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
| 4.1 8 mg/m²/d |
2 |
1038 |
Hazard Ratio (Fixed, 95% CI) |
0.85 [0.74, 0.99] |
| 4.2 9 mg/m²/d |
1 |
416 |
Hazard Ratio (Fixed, 95% CI) |
0.90 [0.73, 1.12] |
| 4.3 10 mg/m²/d |
1 |
1438 |
Hazard Ratio (Fixed, 95% CI) |
0.94 [0.82, 1.08] |
| 4.4 12 mg/m²/d |
7 |
2870 |
Hazard Ratio (Fixed, 95% CI) |
0.92 [0.84, 1.00] |
| 4.5 13 mg/m²/d |
1 |
214 |
Hazard Ratio (Fixed, 95% CI) |
0.70 [0.52, 0.94] |
| 5 OS‐subgroup analysis by total dose of DNR |
12 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
| 5.1 < 180 mg/m2
|
8 |
3109 |
Hazard Ratio (Fixed, 95% CI) |
0.89 [0.82, 0.97] |
| 5.2 ≧ 180 mg/m2
|
4 |
2867 |
Hazard Ratio (Fixed, 95% CI) |
0.91 [0.82, 1.00] |
| 6 OS‐subgroup analysis by dose of IDA versus dose of DNR |
12 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
| 6.1 9 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
416 |
Hazard Ratio (Fixed, 95% CI) |
0.90 [0.73, 1.12] |
| 6.2 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
3 |
701 |
Hazard Ratio (Fixed, 95% CI) |
0.94 [0.81, 1.09] |
| 6.3 13 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
214 |
Hazard Ratio (Fixed, 95% CI) |
0.70 [0.52, 0.94] |
| 6.4 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Hazard Ratio (Fixed, 95% CI) |
0.86 [0.65, 1.13] |
| 6.5 10 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
1438 |
Hazard Ratio (Fixed, 95% CI) |
0.94 [0.82, 1.08] |
| 6.6 12 mg/m²/d IDA versus 50 mg/m²/d DNR |
2 |
1180 |
Hazard Ratio (Fixed, 95% CI) |
0.97 [0.83, 1.14] |
| 6.7 8 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
818 |
Hazard Ratio (Fixed, 95% CI) |
0.85 [0.71, 1.02] |
| 6.8 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
2 |
989 |
Hazard Ratio (Fixed, 95% CI) |
0.83 [0.71, 0.98] |
| 7 OS‐subgroup analysis by age |
6 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
| 7.1 < 15 years |
1 |
521 |
Hazard Ratio (Fixed, 95% CI) |
1.07 [0.78, 1.47] |
| 7.2 ≥ 15 years to < 60 years |
3 |
2376 |
Hazard Ratio (Fixed, 95% CI) |
0.88 [0.80, 0.98] |
| 7.3 ≥ 60 years |
2 |
527 |
Hazard Ratio (Fixed, 95% CI) |
0.95 [0.79, 1.15] |
| 8 OS‐subgroup analysis by cytogenetic risk stratification |
1 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
| 8.1 Favourable |
1 |
123 |
Hazard Ratio (Fixed, 95% CI) |
0.51 [0.23, 1.12] |
| 8.2 Intermediate |
1 |
468 |
Hazard Ratio (Fixed, 95% CI) |
0.70 [0.54, 0.90] |
| 8.3 Adverse |
1 |
174 |
Hazard Ratio (Fixed, 95% CI) |
0.94 [0.67, 1.31] |
| 9 DFS‐overall analysis |
8 |
3070 |
Hazard Ratio (Fixed, 95% CI) |
0.88 [0.81, 0.96] |
| 10 DFS‐sensitivity analysis by random‐effects model |
8 |
3070 |
Hazard Ratio (Random, 95% CI) |
0.88 [0.80, 0.96] |
| 11 DFS‐subgroup analysis by dose of IDA |
8 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
| 11.1 8 mg/m²/d |
2 |
816 |
Hazard Ratio (Fixed, 95% CI) |
0.82 [0.69, 0.98] |
| 11.2 10 mg/m²/d |
1 |
975 |
Hazard Ratio (Fixed, 95% CI) |
0.85 [0.71, 1.02] |
| 11.3 12 mg/m²/d |
4 |
1145 |
Hazard Ratio (Fixed, 95% CI) |
0.96 [0.85, 1.08] |
| 11.4 13 mg/m²/d |
1 |
134 |
Hazard Ratio (Fixed, 95% CI) |
0.64 [0.43, 0.94] |
| 12 DFS‐subgroup analysis by total dose of DNR |
8 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
| 12.1 < 180 mg/m2
|
6 |
1573 |
Hazard Ratio (Fixed, 95% CI) |
0.84 [0.75, 0.94] |
| 12.2 ≧ 180 mg/m2
|
2 |
1497 |
Hazard Ratio (Fixed, 95% CI) |
0.94 [0.83, 1.07] |
| 13 DFS‐subgroup analysis by dose of IDA versus dose of DNR |
8 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
| 13.1 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
3 |
322 |
Hazard Ratio (Fixed, 95% CI) |
0.90 [0.74, 1.09] |
| 13.2 13 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
134 |
Hazard Ratio (Fixed, 95% CI) |
0.64 [0.43, 0.94] |
| 13.3 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
142 |
Hazard Ratio (Fixed, 95% CI) |
0.78 [0.58, 1.04] |
| 13.4 10 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
975 |
Hazard Ratio (Fixed, 95% CI) |
0.85 [0.71, 1.02] |
| 13.5 12 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
823 |
Hazard Ratio (Fixed, 95% CI) |
1.0 [0.85, 1.17] |
| 13.6 8 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
674 |
Hazard Ratio (Fixed, 95% CI) |
0.84 [0.68, 1.05] |
| 14 DFS‐subgroup analysis by cytogenetic risk stratification |
1 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
| 14.1 Favourable |
1 |
118 |
Hazard Ratio (Fixed, 95% CI) |
0.88 [0.47, 1.64] |
| 14.2 Intermediate |
1 |
393 |
Hazard Ratio (Fixed, 95% CI) |
0.73 [0.56, 0.97] |
| 14.3 Adverse |
1 |
113 |
Hazard Ratio (Fixed, 95% CI) |
0.93 [0.62, 1.41] |
| 15 CR‐overall analysis |
18 |
6692 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [1.01, 1.07] |
| 16 CR‐sensitivity analysis by random‐effects model |
18 |
6692 |
Risk Ratio (M‐H, Random, 95% CI) |
1.05 [1.01, 1.10] |
| 17 CR‐subgroup analysis by dose of IDA |
17 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 17.1 8 mg/m²/d |
3 |
1083 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.03 [0.97, 1.09] |
| 17.2 9 mg/m²/d |
1 |
416 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.09 [0.92, 1.29] |
| 17.3 10 mg/m²/d |
2 |
1462 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.92, 1.06] |
| 17.4 12 mg/m²/d |
10 |
3446 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.05 [1.01, 1.09] |
| 17.5 13 mg/m²/d |
1 |
214 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.15 [0.94, 1.42] |
| 18 CR‐subgroup analysis by total dose of DNR |
18 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 18.1 < 180 mg/m2
|
13 |
3671 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.06 [1.01, 1.11] |
| 18.2 ≥ 180 mg/m2
|
5 |
3021 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.02 [0.98, 1.06] |
| 19 CR‐subgroup analysis by dose of IDA versus dose of DNR |
17 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 19.1 8 mg/m²/d IDA versus 25 mg/m²/d DNR |
1 |
45 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.14 [0.64, 2.03] |
| 19.2 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.46 [0.88, 2.43] |
| 19.3 9 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
416 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.09 [0.92, 1.29] |
| 19.4 10 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
24 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.38 [0.90, 12.74] |
| 19.5 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
3 |
701 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.12 [0.97, 1.31] |
| 19.6 13 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
214 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.15 [0.94, 1.42] |
| 19.7 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.11 [0.91, 1.35] |
| 19.8 10 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
1438 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.91, 1.05] |
| 19.9 12 mg/m²/d IDA versus 50 mg/m²/d DNR |
2 |
1177 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.97, 1.10] |
| 19.10 8 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.95, 1.07] |
| 19.11 12 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
358 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.91, 1.07] |
| 19.12 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
2 |
989 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.05 [0.99, 1.11] |
| 19.13 12 mg/m²/d IDA versus 90 mg/m²/d DNR |
1 |
157 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.84, 1.16] |
| 20 CR‐subgroup analysis by age |
11 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 20.1 < 15 years |
1 |
521 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.93, 1.05] |
| 20.2 ≥ 15 years to < 60 years |
8 |
3294 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [1.00, 1.08] |
| 20.3 ≥ 60 years |
6 |
751 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.08 [0.95, 1.22] |
| 21 CR‐subgroup analysis by cytogenetic risk stratification |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 21.1 Favourable |
2 |
280 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.88, 1.01] |
| 21.2 Intermediate |
3 |
1080 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.98, 1.11] |
| 21.3 Adverse |
3 |
359 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.12 [0.97, 1.28] |
| 22 Death on induction therapy‐overall analysis |
14 |
6349 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [1.01, 1.36] |
| 23 Death on induction therapy‐sensitivity analysis by random‐effects model |
14 |
6349 |
Risk Ratio (M‐H, Random, 95% CI) |
1.17 [0.97, 1.41] |
| 24 Death on induction therapy‐subgroup analysis by dose of IDA |
14 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 24.1 8 mg/m²/d |
2 |
1038 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.20 [0.79, 1.83] |
| 24.2 9 mg/m²/d |
1 |
416 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.51, 1.65] |
| 24.3 10 mg/m²/d |
2 |
1462 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.09 [0.83, 1.41] |
| 24.4 12 mg/m²/d |
8 |
3225 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [1.04, 1.63] |
| 24.5 13 mg/m²/d |
1 |
208 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.14 [0.67, 1.96] |
| 25 Death on induction therapy‐subgroup analysis by total dose of DNR |
14 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 25.1 < 180 mg/m2
|
10 |
3485 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.17 [1.00, 1.38] |
| 25.2 ≧ 180 mg/m2
|
4 |
2864 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.19 [0.83, 1.70] |
| 26 Death on induction therapy‐subgroup analysis by dose of IDA versus dose of DNR |
14 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 26.1 9 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
416 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.51, 1.65] |
| 26.2 10 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
24 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.34 [0.08, 1.41] |
| 26.3 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
3 |
701 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.98, 1.70] |
| 26.4 13 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
208 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.14 [0.67, 1.96] |
| 26.5 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.39 [0.78, 2.48] |
| 26.6 10 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
1438 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.87, 1.48] |
| 26.7 12 mg/m²/d IDA versus 50 mg/m²/d DNR |
2 |
1177 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.91 [1.04, 3.53] |
| 26.8 8 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.56, 1.91] |
| 26.9 12 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
358 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.72 [0.59, 5.04] |
| 26.10 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
2 |
989 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.77 [0.42, 1.42] |
| 27 Death on induction therapy‐subgroup analysis by age |
6 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 27.1 < 15 years |
1 |
521 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.36 [0.44, 4.24] |
| 27.2 ≥ 15 years to < 60 years |
4 |
2390 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.08 [0.85, 1.37] |
| 27.3 ≥ 60 years |
2 |
426 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.53, 1.60] |
| 28 Relapse‐overall analysis |
4 |
1091 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.80, 0.98] |
| 29 Relapse‐sensitivity analysis by random‐effects model |
4 |
1091 |
Risk Ratio (M‐H, Random, 95% CI) |
0.85 [0.71, 1.01] |
| 30 Relapse‐subgroup analysis by dose of IDA |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 30.1 8 mg/m²/d |
1 |
131 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.75 [0.66, 0.86] |
| 30.2 12 mg/m²/d |
3 |
960 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.81, 1.04] |
| 31 Relapse‐subgroup analysis by total dose of DNR |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 31.1 < 180 mg/m2
|
2 |
271 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.74 [0.65, 0.85] |
| 31.2 ≧ 180 mg/m2
|
2 |
820 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.84, 1.13] |
| 32 Relapse‐subgroup analysis by dose of IDA versus dose of DNR |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 32.1 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
140 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.72 [0.56, 0.93] |
| 32.2 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
131 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.75 [0.66, 0.86] |
| 32.3 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
2 |
820 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.84, 1.13] |
| 33 Nausea/vomiting grade 3/4‐overall analysis |
4 |
622 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.12 [0.73, 1.73] |
| 34 Nausea/vomiting grade 3/4‐sensitivity analysis by random‐effects model |
4 |
622 |
Risk Ratio (M‐H, Random, 95% CI) |
1.07 [0.69, 1.65] |
| 35 Nausea/vomiting grade 3/4‐subgroup analysis by dose of IDA |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 35.1 8 mg/m²/d |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [0.51, 2.73] |
| 35.2 12 mg/m²/d |
3 |
402 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.10 [0.67, 1.82] |
| 36 Nausea/vomiting grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 36.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.69 [0.35, 1.39] |
| 36.2 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
218 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.15 [0.55, 8.39] |
| 36.3 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [0.51, 2.73] |
| 36.4 12 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
120 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.43 [0.58, 3.50] |
| 37 Alopecia grade 3/4‐overall analysis |
4 |
715 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.08 [0.90, 1.31] |
| 38 Alopecia grade 3/4‐sensitivity analysis by random‐effects model |
4 |
715 |
Risk Ratio (M‐H, Random, 95% CI) |
1.08 [0.86, 1.35] |
| 39 Alopecia grade 3/4‐subgroup analysis by dose of IDA |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 39.1 8 mg/m²/d |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.77, 1.30] |
| 39.2 12 mg/m²/d |
2 |
281 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.37 [0.92, 2.04] |
| 39.3 13 mg/m²/d |
1 |
214 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.69, 1.41] |
| 40 Alopecia grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 40.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
63 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.80 [0.34, 1.89] |
| 40.2 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
218 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.59 [1.01, 2.51] |
| 40.3 13 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
214 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.69, 1.41] |
| 40.4 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.77, 1.30] |
| 41 Diarrhoea grade 3/4‐overall analysis |
3 |
502 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.25 [0.68, 2.28] |
| 42 Diarrhoea grade 3/4‐sensitivity analysis by random‐effects model |
3 |
502 |
Risk Ratio (M‐H, Random, 95% CI) |
1.25 [0.68, 2.29] |
| 43 Diarrhoea grade 3/4‐subgroup analysis by dose of IDA |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 43.1 8 mg/m²/d |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.14, 6.72] |
| 43.2 12 mg/m²/d |
2 |
282 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.68, 2.43] |
| 44 Diarrhoea grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 44.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.07, 15.30] |
| 44.2 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
218 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.31 [0.68, 2.52] |
| 44.3 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.14, 6.72] |
| 45 Hepatic toxicity grade 3/4‐overall analysis |
5 |
1226 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.84 [0.59, 1.20] |
| 46 Hepatic toxicity grade 3/4‐sensitivity analysis by random‐effects model |
5 |
1226 |
Risk Ratio (M‐H, Random, 95% CI) |
0.93 [0.57, 1.52] |
| 47 Hepatic toxicity grade 3/4‐subgroup analysis by dose of IDA |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 47.1 8 mg/m²/d |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.44, 2.13] |
| 47.2 12 mg/m²/d |
4 |
1006 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.81 [0.54, 1.21] |
| 48 Hepatic toxicity grade 3/4‐subgroup analysis by total dose of DNR |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 48.1 < 180 mg/m2
|
4 |
743 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.25 [0.75, 2.07] |
| 48.2 ≧ 180 mg/m2
|
1 |
483 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.32, 0.93] |
| 49 Hepatic toxicity grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 49.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.5 [0.27, 8.38] |
| 49.2 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
2 |
459 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.47 [0.72, 3.01] |
| 49.3 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.44, 2.13] |
| 49.4 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
1 |
483 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.32, 0.93] |
| 50 Renal toxicity grade 3/4‐overall analysis |
4 |
743 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.73 [0.75, 4.00] |
| 51 Renal toxicity grade 3/4‐sensitivity analysis by random‐effects model |
4 |
743 |
Risk Ratio (M‐H, Random, 95% CI) |
1.68 [0.70, 4.04] |
| 52 Renal toxicity grade 3/4‐subgroup analysis by dose of IDA |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 52.1 8 mg/m²/d |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.14, 6.72] |
| 52.2 12 mg/m²/d |
3 |
523 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.98 [0.77, 5.05] |
| 53 Renal toxicity grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 53.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.13, 71.00] |
| 53.2 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
2 |
459 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.89 [0.71, 5.05] |
| 53.3 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.14, 6.72] |
| 54 Cardiac toxicity grade 3/4‐overall analysis |
6 |
2795 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.70, 1.37] |
| 55 Cardiac toxicity grade 3/4‐sensitivity analysis by random‐effects model |
6 |
2795 |
Risk Ratio (M‐H, Random, 95% CI) |
0.98 [0.67, 1.43] |
| 56 Cardiac toxicity grade 3/4‐subgroup analysis by dose of IDA |
6 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 56.1 8 mg/m²/d |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.61, 1.59] |
| 56.2 12 mg/m²/d |
5 |
1977 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.60, 1.57] |
| 57 Cardiac toxicity grade 3/4‐subgroup analysis by total dose of DNR |
6 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 57.1 < 180 mg/m2
|
3 |
523 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.36, 1.28] |
| 57.2 ≧ 180 mg/m2
|
3 |
2272 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.14 [0.76, 1.70] |
| 58 Cardiac toxicity grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
6 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 58.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.01, 7.89] |
| 58.2 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
2 |
459 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.71 [0.37, 1.35] |
| 58.3 12 mg/m²/d IDA versus 50 mg/m²/d DNR |
2 |
1121 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.65 [0.67, 4.05] |
| 58.4 8 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.61, 1.59] |
| 58.5 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
1 |
397 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.07 [0.29, 3.92] |
| 59 Skin toxicity grade 3/4‐overall analysis |
3 |
761 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.02 [0.47, 2.23] |
| 60 Skin toxicity grade 3/4‐sensitivity analysis by random‐effects model |
3 |
761 |
Risk Ratio (M‐H, Random, 95% CI) |
1.02 [0.41, 2.50] |
| 61 Skin toxicity grade 3/4‐subgroup analysis by total dose of DNR |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 61.1 < 180 mg/m2
|
2 |
282 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.66 [0.45, 6.18] |
| 61.2 ≧ 180 mg/m2
|
1 |
479 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.28, 2.07] |
| 62 Skin toxicity grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 62.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.01, 7.89] |
| 62.2 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
218 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.69 [0.53, 13.57] |
| 62.3 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
1 |
479 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.28, 2.07] |
| 63 Central neurotoxicity grade 3/4‐overall analysis |
2 |
707 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.49, 3.35] |
| 64 Central neurotoxicity grade 3/4‐sensitivity analysis by random‐effects model |
2 |
707 |
Risk Ratio (M‐H, Random, 95% CI) |
1.28 [0.49, 3.35] |
| 65 Central neurotoxicity grade 3/4‐subgroup analysis by dose of IDA |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 65.1 8 mg/m²/d |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.20, 4.67] |
| 65.2 12 mg/m²/d |
1 |
487 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.52 [0.45, 5.11] |
| 66 Central neurotoxicity grade 3/4‐subgroup analysis by total dose of DNR |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 66.1 < 180 mg/m2
|
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.20, 4.67] |
| 66.2 ≧ 180 mg/m2
|
1 |
487 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.52 [0.45, 5.11] |
| 67 Central neurotoxicity grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 67.1 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.20, 4.67] |
| 67.2 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
1 |
487 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.52 [0.45, 5.11] |
| 68 Bleeding grade 3/4‐overall analysis |
4 |
2299 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.65, 1.45] |
| 69 Bleeding grade 3/4‐sensitivity analysis by random‐effects model |
4 |
2299 |
Risk Ratio (M‐H, Random, 95% CI) |
0.97 [0.65, 1.45] |
| 70 Bleeding grade 3/4‐subgroup analysis by dose of IDA |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 70.1 8 mg/m²/d |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.08 [0.60, 1.96] |
| 70.2 12 mg/m²/d |
3 |
1481 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.89 [0.51, 1.53] |
| 71 Bleeding grade 3/4‐subgroup analysis by total dose of DNR |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 71.1 < 180 mg/m2
|
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.13, 71.00] |
| 71.2 ≧ 180 mg/m2
|
3 |
2235 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.63, 1.42] |
| 72 Bleeding grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 72.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.13, 71.00] |
| 72.2 12 mg/m²/d IDA versus 50 mg/m²/d DNR |
2 |
1121 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.48, 1.54] |
| 72.3 8 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.08 [0.60, 1.96] |
| 72.4 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
2 |
1417 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.84 [0.48, 1.48] |
| 73 Stomatitis grade 3/4‐overall analysis |
2 |
284 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.65 [0.78, 3.47] |
| 74 Stomatitis grade 3/4‐sensitivity analysis by random‐effects model |
2 |
284 |
Risk Ratio (M‐H, Random, 95% CI) |
1.59 [0.75, 3.38] |
| 75 Stomatitis grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 75.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.0 [0.47, 33.86] |
| 75.2 8 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.39 [0.62, 3.12] |
| 76 Mucositis grade 3/4‐overall analysis |
5 |
2000 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.22 [1.04, 1.44] |
| 77 Mucositis grade 3/4‐sensitivity analysis by random‐effects model |
5 |
2000 |
Risk Ratio (M‐H, Random, 95% CI) |
1.22 [0.92, 1.61] |
| 78 Mucositis grade 3/4‐subgroup analysis by dose of IDA |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 78.1 8 mg/m²/d |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [1.05, 1.60] |
| 78.2 12 mg/m²/d |
4 |
1182 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.87, 1.47] |
| 79 Mucositis grade 3/4‐subgroup analysis by total dose of DNR |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 79.1 < 180 mg/m2
|
2 |
338 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.14 [0.53, 2.44] |
| 79.2 ≧ 180 mg/m2
|
3 |
1662 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.23 [1.04, 1.45] |
| 80 Mucositis grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 80.1 12 mg/m²/d IDA versus 45 mg/m²/d DNR |
1 |
218 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.75 [0.30, 1.91] |
| 80.2 12 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
120 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.63, 14.27] |
| 80.3 8 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [1.05, 1.60] |
| 80.4 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
2 |
844 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.86, 1.50] |
| 81 Mucositis grade 3/4‐subgroup analysis by age |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 81.1 < 15 years |
1 |
484 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.71, 1.30] |
| 81.2 ≥ 15 years to < 60 years |
2 |
938 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.33 [1.08, 1.63] |
| 82 Infection grade 3/4‐overall analysis |
5 |
3095 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.07 [0.99, 1.14] |
| 83 Infection grade 3/4‐sensitivity analysis by random‐effects analysis |
5 |
3095 |
Risk Ratio (M‐H, Random, 95% CI) |
1.04 [0.97, 1.11] |
| 84 Infection grade 3/4‐subgroup analysis by dose of IDA |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 84.1 8 mg/m²/d |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.94, 1.07] |
| 84.2 10 mg/m²/d |
1 |
1438 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.10 [0.94, 1.28] |
| 84.3 12 mg/m²/d |
3 |
839 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [0.95, 1.47] |
| 85 Infection grade 3/4‐subgroup analysis by total dose of DNR |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 85.1 < 180 mg/m2
|
3 |
1790 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.11 [0.96, 1.29] |
| 85.2 ≧ 180 mg/m2
|
2 |
1305 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.97, 1.11] |
| 86 Infection grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 86.1 12 mg/m²/d IDA versus 40 mg/m²/d DNR |
1 |
64 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.43, 2.34] |
| 86.2 10 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
1438 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.10 [0.94, 1.28] |
| 86.3 8 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
818 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.94, 1.07] |
| 86.4 12 mg/m²/d IDA versus 60 mg/m²/d DNR |
1 |
288 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.28 [0.78, 2.10] |
| 86.5 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
1 |
487 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [0.91, 1.51] |
| 87 Infection grade 3/4‐subgroup analysis by age |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 87.1 < 15 years |
1 |
487 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [0.91, 1.51] |
| 87.2 ≥ 15 years to < 60 years |
2 |
2256 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.97, 1.12] |
| 88 Sepsis grade 3/4‐overall analysis |
2 |
1417 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [0.96, 1.77] |
| 89 Sepsis grade 3/4‐sensitivity analysis by random‐effects model |
2 |
1417 |
Risk Ratio (M‐H, Random, 95% CI) |
1.30 [0.74, 2.28] |
| 90 Sepsis grade 3/4‐subgroup analysis by dose of IDA versus dose of DNR |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 90.1 12 mg/m²/d IDA versus 50 mg/m²/d DNR |
1 |
1057 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.75 [1.10, 2.78] |
| 90.2 12 mg/m²/d IDA versus 80 mg/m²/d DNR |
1 |
360 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.66, 1.47] |
